Allogene Therapeutics
Clinical trials sponsored by Allogene Therapeutics, explained in plain language.
-
Engineered immune cells take on Hard-to-Treat kidney cancer
Disease control OngoingThis early-phase study tests a new treatment called ALLO-316 for people with advanced or metastatic clear cell renal cell carcinoma who have already tried other therapies. The treatment uses specially designed immune cells (CAR T cells) from a donor, along with chemotherapy to pr…
Phase: PHASE1 • Sponsor: Allogene Therapeutics • Aim: Disease control
Last updated May 26, 2026 08:12 UTC
-
New CAR t therapy offers hope for Hard-to-Treat blood cancers
Disease control OngoingThis study tests a new treatment called ALLO-501A, a type of CAR T cell therapy made from donor cells, for adults with large B-cell lymphoma or CLL/SLL that has come back or not responded to other treatments. The goal is to see if it is safe and effective at controlling the cance…
Phase: PHASE1, PHASE2 • Sponsor: Allogene Therapeutics • Aim: Disease control
Last updated May 26, 2026 08:11 UTC